Industry Roundup: Spiked Bee Pollen Products; NAD Endorsement Claim Spiked; DSM Venturing Backs Natreo
This article was originally published in The Tan Sheet
Executive Summary
Spiked bee pollen products; NAD endorsement claim shut down; DSM Venturing backs Natreo; Creative Medical prepares to distribute; more news in brief.
You may also be interested in...
American Dream's Nightmare Ends, But It Doubts NAD Standard For Claims
Dietary supplement multi-level marketer American Dream says it will comply with NAD's recommendations even though "it disagrees with the standard NAD applied to its claims for its dietary supplement."
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.